Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.52 |
| ▸ | HRH1 | P35367 | 3/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593942 | 1.00 | HTR2A (0.52) | HTR2AHRH1RETHTR2CIDO1 | |
| Hydrochloric Acid SCHEMBL1571970 | 0.97 | IDO1 (0.55) | HTR2AHRH1RETHTR2CIDO1 | |
| SCHEMBL1689733 | 0.84 | PLAU (0.55) | HTR2AHRH1RETHTR2CIDO1 | |
| Hydrochloric Acid SCHEMBL9688132 | 0.83 | PLAU (0.53) | HTR2AHRH1RETHTR2CIDO1 | |
| SCHEMBL4068954 | 0.81 | SIGMAR1 (0.50) | HTR2AHRH1RETHTR2CIDO1 | |
| SCHEMBL6992991 | 0.80 | IDO1 (0.59) | HTR2AHRH1RETHTR2CIDO1 | |
| SCHEMBL31536940 | 0.80 | IDO1 (0.59) | HTR2AHRH1RETHTR2CIDO1 | |
| Hydrochloric Acid SCHEMBL7212472 | 0.78 | IDO1 (0.62) | HTR2AHRH1RETHTR2CIDO1 | |
| SCHEMBL7444973 | 0.77 | HTR2A (0.58) | HTR2AHRH1RETHTR2CIDO1 | |
| SCHEMBL2840630 | 0.75 | PLAU (0.50) | HTR2AHRH1RETHTR2CIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8113554-A | — | — | None | — | — | JP | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4204411-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | Nalo Therapeutics (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20180273528-A1 | IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2018-09-27 | — | — | US | disclosed |
| EP-3356363-A1 | NEW IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS DUAL DYRK1/CLK1 INHIBITORS | Les Laboratoires Servier (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9499533-B2 | Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity | SHIONOGI & CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-5750524-A | ADMINISTERING AN SULFAMIDE SUBSTITUTED INDAN DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0483667-B1 | Cyclic imino derivatives, process for their preparation and drugs containing them | THOMAE GMBH DR K (DE) | 1998-02-04 | — | — | EP | disclosed |
| EP-0773019-A1 | HYPERLIPEMIA REMEDY | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-14 | — | — | EP | disclosed |
| US-5591769-A | PYRROLIDINE DERIVATIVES; ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5541343-A | ANTIAGGLOMERANTS FOR CELLS OR ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| EP-0589037-B1 | INDIAN DERIVATIVE AND THROMBOXANE ANTAGONIST CONTAINING THE SAME | ZERIA PHARM CO LTD (JP) | 1996-05-29 | — | — | EP | disclosed |
| JP-H08113554-A | PRODUCTION OF 2-INDANYLMETHYLAMINE, N-BENZYL-N-(2-INDANYLMETHYL)AMINE AND ITS PRODUCTION | ZERIA PHARMACEUT CO LTD | 1996-05-07 | — | — | JP | disclosed |
| US-5409956-A | A sulfonylaminoalkylindan carboxylic acid or ester for treating thrombosis, vasospasm or asthma | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1995-04-25 | — | — | US | disclosed |
| EP-0589037-A1 | INDIAN DERIVATIVE AND THROMBOXANE ANTAGONIST CONTAINING THE SAME | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-30 | — | — | EP | disclosed |
| EP-0483667-A2 | Cyclic imino derivatives, process for their preparation and drugs containing them | Dr. Karl Thomae GmbH (DE) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273528-A1 | IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDH2, CYP4B1, RB1 | HTR2A 1918/4885HRH1 1310/4885RET 344/4885 |
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | TRPV4, TRPC4, TRPV2 | HTR2A 304/4885HRH1 401/4885RET 700/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | HTR2A 3949/4885HRH1 4106/4885RET 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.